Natural Alternatives International, Inc. (NASDAQ: NAII) is a Carlsbad, California-based contract manufacturer and marketer of nutritional supplements, operating a private-label manufacturing business alongside its patented CarnoSyn beta-alanine ingredient lines. After a steep multi-year decline, the micro-cap stock now trades near $1.00, and investors are asking whether a recovery toward the $1.50 level is realistic.
Unlike larger, widely covered names, NAII carries no reliable sell-side price targets. Yahoo Finance lists no one-year target estimate, Benzinga reports no consensus figure, and MarketBeat shows a consensus target of "N/A." The only published "rating" is a Weiss Ratings letter grade, currently a Sell, which does not attach a dollar price target. A handful of aggregator sites circulate widely inconsistent figures, including obvious data-entry errors, so no trustworthy analyst aggregate exists.
Because of this, the $1.50 objective is a fallback target grounded in public and technical discussion rather than analyst forecasts. The stock has collapsed from a 52-week high of $4.96 to near $0.94, and its 50-day moving average now sits at roughly $1.48. A move back to the round $1.50 area — essentially reclaiming that moving average — is the realistic mean-reversion milestone most frequently discussed for the shares. It is a technical recovery level, not a published analyst price target.
The shares have been trading near $1.00, with a market capitalization of roughly $6 million and a 52-week range of $0.94 to $4.96. Reaching $1.50 would require a gain of about 50% from the $1.00 level — a very large move for any equity, and an especially demanding one for a loss-making micro-cap in a persistent downtrend.
A credible path toward $1.50 would likely require two things to align. Fundamentally, the company would need to demonstrate a return toward profitability and margin repair. Technically, the stock would first need to hold the $1.00 psychological level and the $0.94 low, then reclaim the $1.50 zone that now acts as resistance.
Several factors could support a recovery. First, the valuation is depressed: the shares trade at roughly 0.12 times book value, well below the company's net asset base. Second, Chairman and CEO Mark A. LeDoux bought shares in early 2026 at prices between roughly $2.66 and $2.85, signaling insider confidence at levels far above the current quote. Third, management is restructuring — consolidating U.S. manufacturing into its Vista, California facility and planning to sell the underutilized Carlsbad site to add liquidity and reduce debt. Fourth, revenue is growing, with fiscal 2026 net sales up about 10% to $142.5 million, and the company has initiated a strategic-alternatives review that could surface value.
The obstacles are significant. NAII posted a fiscal fourth-quarter 2026 net loss of $13.5 million, including a $10.4 million non-cash impairment tied to the Carlsbad facility, and management guided to a full-year net loss. Gross margin contracted to 5% from 10.4% year over year amid factory underutilization. Cash and equivalents fell to $7.4 million as of June 30, 2026, from $12.3 million a year earlier. The business is also highly concentrated: private-label contract manufacturing accounted for roughly 94.5% of fiscal 2026 revenue, with a portion dependent on a single large customer. With no near-term path to profitability signaled, valuation alone may not be enough to reverse the downtrend.
The chart shows a prolonged decline, with the stock down sharply over one, three, and five years and trading below both its 50-day (about $1.48) and 200-day (about $2.34) moving averages. The 52-week low near $0.94 and the $1.00 round number form the immediate support zone. The first meaningful resistance is the $1.50 area — the round level and the 50-day average — followed by the 200-day average near $2.34. A sustained close below $0.94 would signal further downside rather than a recovery.
Analyst price targets typically reflect a roughly 12-month research horizon, but since no credible analyst targets exist here, the $1.50 level carries no fixed timeframe. Investors should watch the next quarterly report (the fiscal first quarter of 2027, expected around late November 2026), progress on the Carlsbad facility sale and strategic review, gross-margin trends, cash balances, and any further insider activity. Revenue growth that fails to translate into earnings would limit any sustained re-rating.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, thinly traded micro-cap like NAII, such tools can help traders spot shifts in trend and momentum more efficiently than manual chart review. Traders can use these signals to discover opportunities, monitor existing positions, and identify changing market structure as it develops.
The question of whether NAII can reach $1.50 is ultimately a question of whether a deeply discounted, loss-making contract manufacturer can begin repairing margins and rebuilding investor confidence. The target is a technical mean-reversion level tied to the 50-day moving average, not an analyst consensus, and it implies a very large roughly 50% move from current levels. Insider buying, a sub-book valuation, and restructuring efforts offer a plausible foundation, but persistent losses, margin compression, impairment charges, and customer concentration weigh heavily against the stock. Investors should monitor earnings, the asset-sale and strategic-review process, and whether the shares can hold above the $0.94 low before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that NAII and CAG have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NAII and CAG's prices will move in lockstep.
| Ticker / NAME | Correlation To NAII | 1D Price Change % | ||
|---|---|---|---|---|
| NAII | 100% | +1.69% | ||
| CAG - NAII | 24% Poorly correlated | +1.24% | ||
| LFVN - NAII | 22% Poorly correlated | -1.39% | ||
| WEST - NAII | 22% Poorly correlated | -0.71% | ||
| RKDA - NAII | 22% Poorly correlated | -1.80% | ||
| FAMI - NAII | 21% Poorly correlated | -11.13% | ||
More | ||||
| Ticker / NAME | Correlation To NAII | 1D Price Change % |
|---|---|---|
| NAII | 100% | +1.69% |
| Food: Major Diversified industry (62 stocks) | 13% Poorly correlated | -0.04% |